Business
VAL201 update
VAL201 update.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 3340R ValiRx PLC 20 September 2017 \n\n \n \n \n \nValiRx Plc\n(\"ValiRx\" or \"the Company\" or \"the Group\")\n \nVAL201 update\n \nThe Company notes speculation as to the status of its VAL201 clinical trial and confirms that the trial is ongoing and looks forward to updating the market in due course.\n \nFurther details of the trial can be found at https://www.clinicaltrials.gov/ct2/show/NCT02280317?term=val201&rank=1\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n*** ENDS ***\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser) \nLiam Murray/Jo Turner/Richard Nash\n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\n\n\n\n\n\n\n\n\nBeaufort Securities Limited (Broker) \nJon Belliss\n\n\nTel: +44 (0) 207 382 8300\n\n\n\n\n \nNotes for Editors \nAbout ValiRx \nValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\n \nThe Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.\n \nValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. \n \nUntil recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the de...